Navigation Links
Global Genomics Group Announces Breakthrough Diagnostic Blood Test for Plaque Detection in the Heart
Date:3/20/2017

ATLANTA, March 20, 2017 /PRNewswire/ -- Global Genomics Group ("G3"), a precision-medicine-based biopharmaceutical company developing genetically validated therapeutics and diagnostics for common, chronic and orphan diseases announced today that the Company's management team will be presenting updated data on their first precision diagnostic biomarker, "knowPLAQUETM", for the detection of atherosclerotic coronary artery disease at the 2017 Biomarker Summit in San Diego, CA, on March 20, 2017. "knowPLAQUETM" is the lead product in the Company's diagnostic biomarker portfolio; it is a mass-spectrometry-based metabolomics diagnostic biomarker signature for the detection of atherosclerotic coronary artery disease, based on a simple mass spectrometry measurement from a standard blood draw.

"knowPLAQUETM" is the first diagnostic blood test that was specifically designed and developed for the identification of patients with any plaque in their coronary arteries. Atherosclerosis is the underlying malevolent abnormality responsible for coronary artery disease, which can result in heart attack, stroke and sudden cardiac death. When patients present with chest pain in the outpatient setting, the test can be used to "rule out" the presence of any plaque in the heart. Positioning this test as a "gatekeeper" to the current clinical evaluation paradigm can eliminate a significant number of unnecessary nuclear stress tests and invasive angiograms, and could save approximately 46% in the costs associated with the evaluation of chest pain patients - possibly saving several billion dollars to the US healthcare system.

"We are very pleased with the outstanding diagnostic performance of "knowPLAQUETM", said Szilard Voros, MD, founder and CEO of Global Genomics Group, who is presenting data on the test at the 2017 Biomarker Summit. "We completed the scientific discovery and validation of this diagnostic biomarker signature, and we are in discussions for the implementation of the test. It is terrific to see that novel, cutting-edge scientific insights can be translated to patient care, which can significantly impact and improve the detection of cardiovascular disease."

"knowPLAQUETM" was discovered and validated in Global Genomics Group's own GLOBAL (Genetic Loci and the Burden of Atherosclerotic Lesions; NCT01738828) clinical study, which recruited a total of approximately 7,500 patients, and the test was developed and validated in a total of 1,096 subjects. The study was specifically designed based on the Institute of Medicine Guidelines and the American Heart Association guidelines for biomarker discovery and validation. Initial results from the study were presented last year at the Society of Cardiovascular Computed Tomography meeting in Orlando, FL.

About Global Genomics Group (G3)

G3 is a global leader in pan-omics and investigates biological networks that lead to the development of disease to identify novel biomarkers and therapeutics. G3 combines precision phenotyping with pan-omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and lipoprotein proteomics) and systems-biology driven bioinformatics to investigate the development and progression of conditions such as atherosclerosis in cardiovascular disease.

For additional information, please visit www.globalgenomicsgroup.com

G3 Contact:
Idean Marvasty
VP, Finance and Operations
idean.marvasty@globalgenomicsgroup.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-genomics-group-announces-breakthrough-diagnostic-blood-test-for-plaque-detection-in-the-heart-300425836.html


'/>"/>
SOURCE Global Genomics Group (G3)
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. U.S. Continues to be at the Forefront of Global Demand for Digital Mobile X-rays
2. Global Photomedicine Market Expected to Reach $5,512 Million by 2022-Allied Market Research
3. Global ENT and Bronchoscopy Devices Market Expected to Reach $24,999 Million by 2022 - Allied Market Research
4. Global Surgical Navigation Systems Market Expected to Reach $963 Million by 2022 - Allied Market Research
5. Advanced Wound Care Market is Expected to Reach $12,454 Million, Globally by 2022 - Allied Market Research
6. Global Rheumatoid Arthritis Drug Market Outlook 2022
7. Amgen To Present At The Oppenheimer Global Health Care Conference
8. Pharmaceutical Hot Melt Extrusion Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
9. Global Photopheresis Products Market Forecast to 2022 - By Therapeutic Area, Product & End User - Research and Markets
10. Medical Ceramics Market is Expected to Reach $5,841 Million by 2022, Globally-Allied Market Research
11. Medical Nonwoven Disposables Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
Breaking Medicine News(10 mins):